RCM
ORIAU

Radcliffe Capital Management’s Orion Biotech Opportunities Corp. Units ORIAU Stock Holding History

Radcliffe Capital Management’s Portfolio ORIAU Stock Details ORIAU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-400,000
Closed -$4.02M – 961
2021
Q2 		$4.02M Buy
+400,000
New +$4.03M 0.13% 237

Other funds holding ORIAU

JP
JNE Partners London, United Kingdom $244M AUM 15.73% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Radcliffe Capital Management's ORIAU Position: Q3 2021 in Review

Radcliffe Capital Management sold out of Orion Biotech Opportunities Corp. Units (ORIAU) in Q3 2021, closing a stake of 400,000 shares — an estimated $4.02M sold.

Radcliffe Capital Management first reported a position in ORIAU in Q2 2021 and held it in 1 quarter. The position peaked at $4.02M in Q2 2021. 21 funds tracked by Wall St. Rank hold ORIAU as of Q3 2021.

  • Radcliffe Capital Management reported no remaining Orion Biotech Opportunities Corp. Units position as of Q3 2021 after selling out during the quarter.
  • Radcliffe Capital Management sold 400,000 Orion Biotech Opportunities Corp. Units shares in Q3 2021, an estimated $4.02M.
  • Radcliffe Capital Management first reported a position in Orion Biotech Opportunities Corp. Units in Q2 2021 and held it in 1 quarter.
  • Radcliffe Capital Management's Orion Biotech Opportunities Corp. Units position peaked at $4.02M in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Units as of Q3 2021.

Based on Radcliffe Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.